• Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib
  • Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib
  • Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib
  • Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib
  • Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib
  • Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib

Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib

Powder: Yes
Customized: Customized
Certification: GMP, HSE, ISO 9001, USP, BP
Suitable for: Elderly, Adult
State: Powder
Purity: >99%
Samples:
US$ 40/g 1 g(Min.Order)
| Request Sample
Customization:
Diamond Member Since 2021

Suppliers with verified business licenses

Manufacturer/Factory
  • Overview
  • Product Description
  • Product Details
  • Application&Function
  • Specification
Overview

Basic Info.

Model NO.
D-sung Ceritinib
Product Name
Ceritinib
Name
Ceritinib Powder
Appearance
White Powder
Color
White
Grade
Pharmaceutical Grade
Assay
HPLC 99%
Application
Pharmaceutical
Specific
COA
Test Method
HPLC
Shelf Life
2 Years
CAS No.
1032900-25-6
Mf
C28h36cln5o3s
MW
558.14
Melting Point
720.7
Density
1.251
Transport Package
Negotiable
Specification
99%
Trademark
D-sung
Origin
Shaanxi Xi′an
Production Capacity
1000kg/Month

Product Description

Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib
Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib
Product Description
Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder CeritinibPharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib
Product Details
Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib
 
Product Name Ceritinib
Appearance White Powder
CAS No. 1032900-25-6
MF C28H36ClN5O3S
Ceritinib is a drug for the treatment of lung cancer. It is an ALK inhibitor. It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) following treatment with crizotinib.
Application&Function
Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib

1.It is a tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK). It can promote the development of cancer cells by blocking the protein and inhibit the cells expressing EML4-ALK and NPM-ALK fusion protein.
2.Cerinib, a novel ALK inhibitor, is highly active in advanced patients.

Specification
Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder CeritinibPharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder CeritinibPharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib
Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder CeritinibPharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder CeritinibPharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib
Pharmaceutical Intermediate Ceritinib Raw Material Ceritinib Powder Ceritinib
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

You Might Also Like

Diamond Member Since 2021

Suppliers with verified business licenses

Manufacturer/Factory
Management System Certification
ISO 9001, ISO 14001, GMP, HACCP